QuVa Pharma, Inc.: Drug Recall

Recall #D-0113-2026 · 10/10/2025

Class II: Risk

Recall Details

Recall Number: D-0113-2026
Classification: Class II
Product Type: Drug
Recalling Firm: QuVa Pharma, Inc.
Status: Ongoing
Date Initiated: 10/10/2025
Location: Sugar Land, TX, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 75,885 syringes

Reason for Recall

Presence of Particulate Matter

Product Description

R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50

Distribution Pattern

U.S. Nationwide

Other Recalls by QuVa Pharma, Inc.

Class II: Risk 03/06/2025

Lack of Assurance of Sterility
Class II: Risk 03/06/2025

Lack of Assurance of Sterility
Class II: Risk 03/06/2025

Lack of Assurance of Sterility
Class III: Low Risk 09/20/2022

Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).

View all recalls by QuVa Pharma, Inc. →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.